Development asset linked to Steba Biotech in public FDA and regional records.
biotech · Low Grade Upper Tract Urothelial Cancer
Steba Biotech
STEBA Biotech S.A
Steba Biotech drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Toussus-le-Noble, FR HQ
21 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Toussus-le-Noble, FR
- Employees
- 21
- Programs
- 1
- Drugs
- 4
- Patents
- 0
Steba Biotech pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Steba Biotech drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
padeliporfin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Steba Biotech's portfolio.
-
Development asset linked to Steba Biotech in public FDA and regional records.
-
Development asset linked to Steba Biotech in public FDA and regional records.